Scotiabank analyst Louise Chen initiated coverage of Regeneron (REGN) with a Sector Perform rating and $650 price target Published first on TheFly ...

Most patients with chronic rhinosinusitis with nasal polyps no longer used oral corticosteroids after using dupilumab, according to data presented at the American College of Allergy, Asthma & ...

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...

Pfizer seals the deal with Metsera for $10 billion after Novo Nordisk bowed out; President Donald Trump welcomes executives ...

Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and secondary endpoints in a Phase III study in allergic fungal rhinosinusitis ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

In recent days, Regeneron Pharmaceuticals announced detailed positive Phase 2 trial results for two novel factor XI ...

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...